On Jun 19, 2015, we issued an updated research report on ResMed, Inc.RMD. Recently, ResMed faced a major blow as its phase III SERVE-HF study of ASV failed to meet its primary endpoint. In fact, the ...
New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA) Prevalence of OSA in the United States expected to ...
Royal Philips ($PHG) said it is working with ResMed ($RMD) to analyze study data from mid-May showing that the latter company's Adaptive Servo-Ventilation (ASV ...
ResMed, Inc. RMD recently introduced its AirCurve 11 series devices. These are the company’s newest bilevel devices that use two levels of support, inspiratory positive airway pressure and expiratory ...
Safety Signal of Increased Cardiovascular Mortality Found For ASV Therapy In People With Predominant Central Sleep Apnea and Symptomatic Chronic Heart Failure SAN DIEGO, May 13 /PRNewswire/ -- ResMed ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — In a substudy of CAT-HF, patients with HF, sleep-disordered breathing and an implantable cardiac ...
ResMed (NYSE: RMD) today announced Air Solutions, a new forward-thinking connected care solution for treating sleep-disordered breathing that can benefit all stakeholders in the care continuum. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback